Michael Barbella, Managing Editor04.22.23
A new facility, new reimbursement coverage, and new leadership news took top billing on MPO's website this past week.
Zeus led the way with details about its new catheter manufacturing facility in Arden Hills, Minn. The location, scale, and on-site capabilities across R&D, design, and development aim to advance catheter innovation and strengthen Zeus's strategic partnerships with OEMs and medical device customers. Scheduled to open this summer, the custom 75,600-square-foot facility includes an advanced R&D lab and cleanroom equipped with the latest technologies to design, develop, and validate new catheter prototypes in industry-best lead times. It also brings additional capabilities in-house to Zeus, including laser cutting, ablation, and welding.
Runner-up to Zeus' news was the Centers for Medicare and Medicare Services (CMS) release of an updated policy (effective April 16) that will expand continuous glucose monitor (CGM) coverage to more patients with type 2 diabetes. The expanded coverage from the new policy applies to patients being treated with insulin with traditional Medicare coverage, in addition to certain patients who don’t use insulin but have a history of “problematic hypoglycemia”—where blood glucose is lower than normal and can lead to dizziness or becoming unconscious.
LivaNova CEO Damien McDonald's resignation garnered significant pageviews as well. No reasons were given for McDonald’s resignation. The Board of Directors immediately appointed Chair William A. Kozy as interim CEO and retained an international executive search firm to assist with finding a permanent replacement. Kozy will continue as LivaNova’s board chair, and McDonald will stay available to support handover activities until the end of May.
Other traffic drivers this week included the availability of Philips HealthSuite Imaging on Amazon Web Services, and a meta-analysis demonstrating the positive clinical impact of automatic correction bolusing on glucose control in people with type 1 diabetes.
Zeus led the way with details about its new catheter manufacturing facility in Arden Hills, Minn. The location, scale, and on-site capabilities across R&D, design, and development aim to advance catheter innovation and strengthen Zeus's strategic partnerships with OEMs and medical device customers. Scheduled to open this summer, the custom 75,600-square-foot facility includes an advanced R&D lab and cleanroom equipped with the latest technologies to design, develop, and validate new catheter prototypes in industry-best lead times. It also brings additional capabilities in-house to Zeus, including laser cutting, ablation, and welding.
Runner-up to Zeus' news was the Centers for Medicare and Medicare Services (CMS) release of an updated policy (effective April 16) that will expand continuous glucose monitor (CGM) coverage to more patients with type 2 diabetes. The expanded coverage from the new policy applies to patients being treated with insulin with traditional Medicare coverage, in addition to certain patients who don’t use insulin but have a history of “problematic hypoglycemia”—where blood glucose is lower than normal and can lead to dizziness or becoming unconscious.
LivaNova CEO Damien McDonald's resignation garnered significant pageviews as well. No reasons were given for McDonald’s resignation. The Board of Directors immediately appointed Chair William A. Kozy as interim CEO and retained an international executive search firm to assist with finding a permanent replacement. Kozy will continue as LivaNova’s board chair, and McDonald will stay available to support handover activities until the end of May.
Other traffic drivers this week included the availability of Philips HealthSuite Imaging on Amazon Web Services, and a meta-analysis demonstrating the positive clinical impact of automatic correction bolusing on glucose control in people with type 1 diabetes.
